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| INTRODUC TI ON
T-cell lineage acute lymphoblastic leukemia is an aggressive hematopoietic malignancy accounting for 15% of pediatric ALLs.
1,2
Over the past few decades, the cure rate in T-ALL has significantly increased; however, survival is poor in patients who suffer treatment failure or early relapse.
2, 3 Further improvements in survival for T-ALL will require improved understanding of the mechanism governing leukemogenesis to develop novel treatment approaches.
Although much progress has been made in understanding the stage-specific transformation of T-cell progenitors in leukemic transformation, the mechanisms of epigenetic dysregulation remain less well understood. 4 Genes involved in T-cell receptor signaling and differentiation, and tumor suppressor genes are commonly differentially methylated genes in T-ALL. 5, 6 Hypermethylation of CpG islands located in the promoter and/or 1st exon/intron region was proposed as an alternative mechanism for tumor suppressor gene inactivation.
7-9
The JAK-STAT signaling pathway plays an important role in hematopoietic cell growth, differentiation, and survival. 10 Similar to other leukemias, dysregulation in JAK-STAT signaling networks were found in a subset of T-ALL. 1,10,11 Studies of JAK-STAT activating mutations, including IL7R, JAK1, JAK2, JAK3, and TYK2 have been undertaken, [11] [12] [13] [14] [15] [16] [17] [18] but the potential roles of negative regulators of signal transduction, including SOCS, remain largely unexplored in the pathogenesis of T-ALL.
The SOCS family of cytokine-inducible negative regulators of JAK-STAT and other signaling pathways includes 8 structurally related family members, SOCS1-7 and CIS, all of which contain a central Src-homology 2 domain and a conserved C-terminal domain termed the SOCS box. 19, 20 There is growing evidence implicating SOCS family members in a range of inflammatory diseases and tumors, including hepatocellular carcinoma, colorectal, cervical, and breast cancer. [20] [21] [22] [23] Downregulation of SOCS genes was reported in solid tumors with an unfavorable prognosis and hematological malignancies, including AML, and myeloproliferative disorders. 21, 22, [24] [25] [26] [27] SOCS5 is expressed in a variety of adult tissues, particularly in primary B and T cells located in the spleen, lymph nodes, thymus, and bone marrow. 20, 28 Consistent with its expression in lymphoid organs, SOCS5 has been implicated in Th cell differentiation, particularly in the balance between Th1 and Th2 cells, with SOCS5 preferentially expressed in Th1 cells. 28, 29 Growing evidence suggests SOCS5 is tumor suppressor gene, negatively regulating the epidermal growth factor receptor and JAK-STAT signaling pathways.
24,30-32
However, little is currently known about the mechanisms by which SOCS5 regulates signal transduction in leukemic cells.
Given the roles of SOCS5 in normal T cell development, we hypothesized that SOCS5 is a critical mediator of JAK-STAT signaling and T-ALL progression. Here, we report that SOCS5 is epigenetically regulated by DNA methylation and histone deacetylation. We provide evidence that SOCS5 negatively regulates the activation of the JAK-STAT signaling pathway and cytokine receptors in T-ALL. We show that SOCS5 silencing significantly increases T-ALL proliferation in vitro and leukemia engraftment in a murine model of human leukemia. In summary, we have identified a novel regulator underlying aberrant JAK-STAT activation in T-ALL.
| MATERIAL S AND ME THODS

| Reagents
All reagents were purchased from Thermo Fisher Scientific (Carlsbad, CA, USA) unless specified otherwise.
| Cells and patient samples
Human T-ALL cell lines (MOLT4, ALL-SIL, Jurkat, CCRF-CEM, KoptK1, and PF382) were cultured in RPMI-1640 medium supplemented with 10% FBS, 2 mmol/L L-glutamine, and 100 U/mL penicillin G-streptomycin in a 5% CO 2 incubator at 37°C. The 293-FT and Phoenix cells were maintained following manufacturer instructions.
Murine hematopoietic BaF3 cell line was cultured in RPMI-1640, 10% FBS, 10 ng/mL mouse IL-3 (PeproTech, Rocky Hill, NJ, USA), 2 mmol/L L-glutamine, and 100 U/mL penicillin G-streptomycin. 
K E Y W O R D S
DNA methylation, histone deacetylation, JAK-STAT, signal transduction, T-ALL Resource (Albuquerque, NM, USA) and housed in a specific pathogen-free, AAALAC-accredited facility as described previously.
35
Animals were injected through a tail vein with 1 × 10 6 cells per mouse (T-ALL cells transduced with SOCS5-shRNA or with negative control scrambled shRNA). For survival experiments, animals (10 mice per group) were immediately killed when they showed signs F I G U R E 1 Suppressor of cytokine signaling 5 (SOCS5) negatively regulates T-cell lineage acute lymphoblastic leukemia (T-ALL) proliferation and cell cycle progression. A, SOCS5 mRNA and protein levels in T-ALL cell lines (n = 6). For quantitative real-time (qRT)-PCR analyses, data are means ± SD for 3 independent experiments. B, PF382 and KOPTK1 cells were lentivirally transduced with 4 SOCS5 shRNA (SOCS5 KD1, SOCS5 KD2, SOCS5 KD3, and SOCS5 KD4) and scrambled control (NC), and the decrease in SOCS5 transcript and protein levels was confirmed by qRT-PCR and immunoblotting (**P < .005, *** P < .0005, **** P < .0001). E, Overexpression of SOCS5 mRNA and protein in ALL-SIL and CCRF-CEM cells transduced with SOCS5 expressing plasmid (SOCS5 OE) compared to negative control plasmid (CON) was confirmed by qRT-PCR and immunoblotting (***P < .0005, **** P < .0001). C,F, Growth curves of the transduced T-ALL cell lines were determined by MTS assay. Data are means ± SD for 2 independent experiments carried out in triplicate (repeated measure ANOVA with Tukey's multiple comparisons test (***P < .0005, **** P < .0001). D,G, Cell cycle distribution was carried out 48 h post transduction by propidium iodide staining followed by flow cytometry analyses. Data are representative for 1 of 3 independent experiments of being moribund or had weight loss that exceeded 10%-15% of their total weight. 
| Microarray and RNA sequencing datasets
All of the microarray datasets were from publicly available data resources, including GSE70536 33 and GSE13159. 36 RNA sequencing data was available through the TARGET website, https ://ocg.cancer.gov/ progr ams/target. Data were analyzed as described previously.
1,33,37,38
| Methylation-specific PCR and bisulfite sequencing
Genomic DNA was subjected to bisulfite treatment using the DNA Table S1 . For sequencing, bisulfite-treated genomic DNA was amplified using primers listed in Table S2 . The PCR products were cloned into the Topo TA cloning kit (Thermo Fisher Scientific). Ten randomly picked clones were sequenced (Eurofins Genomics, Luisville, KY, USA) and aligned using Quantification Tool for Methylation Analysis. 
| Chromatin immunoprecipitation
Chromatin immunoprecipitation was carried out on T-ALL cells as described. 40 DNA was immunoprecipitated with anti-HDAC1 (sc-7872X,) 
| Statistical analysis
The statistical analyses were undertaken using GraphPad Prism 7.02 software (GraphPad, La Jolla, CA, USA). The results were considered statistically significant when P < .05. Additional supplementary methods appear in Data S1.
| RE SULTS
| Inactivation of SOCS5 promotes T-ALL cell proliferation
We first analyzed a panel of 6 T-ALL cell lines and found that the SOCS5 gene and protein were differentially expressed ( Figure 1A ).
To investigate the biological roles of SOCS5 in T-ALL, we undertook shRNA-mediated knockdown of SOCS5 in PF382 and KOPTK1 cells Figure 1F ,G). Interestingly, the knockdown and overexpression of SOCS5 had no effect on apoptotic cell death ( Figure S1 ). These results indicate that SOCS5 negatively regulates proliferation of T-ALL cells in vitro.
| SOCS5 negatively regulates MYC and cytokine receptor expression in T-ALL
With evidence that SOCS5 regulates T-ALL proliferation, we stud- Conversely, forced SOCS5 expression reduced MYC protein levels, indicating that SOCS5 could have putative tumor suppressor activity in T-ALL ( Figure 2B ).
| SOCS5 downregulation induces activation of the JAK-STAT signaling pathway
To test whether SOCS5 negatively regulates signal transduction in T-ALL, we examined the JAK-STAT pathway activation in SOCS5-depleted cells compared to the negative control. Silencing of SOCS5 expression markedly enhanced the phosphorylation of STAT1, STAT3, STAT4, STAT5, and STAT6 but had no effect on the total STAT levels ( Figure 2A ). Accordingly, forced SOCS5 expression reduced the activation of the tested STAT proteins, consistent with no changes in their total levels ( Figure 2B ). We next investigated whether SOCS5 preferentially inhibits JAK1, JAK2, JAK3, and TYK2
in T-ALL cells. SOCS5 depletion accelerated JAK1, JAK2, and JAK3 phosphorylation but had modest to no effect on TYK2 (Figures 2A   and S2 ). Conversely, overexpressed SOCS5 inhibited activation of all JAK proteins except for TYK2 in the tested cells ( Figures 2B and S2 ).
As expected, SOCS5 had no effect on total JAK protein levels. Thus, SOCS5 negatively regulates JAK-STAT signaling in T-ALL.
| SOCS5 negatively regulates T-ALL progression in vivo
Because SOCS5 regulates T-ALL cell growth in vitro, we next investigated the effects of SOCS5 expression on T-ALL progression in NSG mice injected with SOCS5-depleted or control cell lines. SOCS5 depletion significantly reduced survival of the engrafted NSG mice (SOCS5 KD1, n = 10; SOCS5 KD2, n = 10) when compared to the F I G U R E 4 Suppressor of cytokine signaling 5 (SOCS5) expression is lowered in acute leukemias with KMT2A gene rearrangements. A, Microarray data analysis of SOCS5 expression in pediatric and young adult T-cell lineage acute lymphoblastic leukemia (T-ALL) patients (n = 100) treated in the COG AALL0434 study (GSE70636). 33 Multiple probe sets were tested. The representative probe set for SOCS5 is shown (209647_s_at). B, SOCS5 expression across distinct molecular/genetic subtypes of T-ALL identified in a cohort of 264 pediatric and young adult T-ALL patients by RNA sequencing (Kruskal-Wallis with Dunn's multiple comparison test, P < .005). 1 C, SOCS5 expression in 173 T-ALL cases classified by recurrent chromosomal rearrangements (TLX3, n = 14; NKX2.1, n = 10; TAL1, n = 77; KMT2A, n = 12; MLLT10, n = 12; LMO2, n = 10; TLX1, n = 17; TAL2, n = 7; HOXA, n = 4) (Kruskal-Wallis with Dunn's multiple comparison test, P < .005).
D, SOCS5
expression in T-ALL with KMT2A gene rearrangements (KMT2A-R) in an independent published cohort of 100 T-ALL cases tested by microarray (unpaired Mann-Whitney U test, **** P < .0001). 33 E, SOCS5 mRNA levels in primary T-ALL samples (n = 25), normal bone marrow CD34 + cells (n = 3), normal PBMC (n = 2), pan T-cells (Pan-T) (n = 3), and normal thymocytes (Thym, n = 3) by quantitative real-time PCR.
Immunoblotting for SOCS5 protein levels in primary T-ALL samples (n = 9), for which cellular material was available. Red text indicates the samples harboring KMT2A-R. F,G, Analysis of SOCS5 mRNA levels in B-cell (B-)ALL and AML with KMT2A-R compared to the remaining cases in a previously reported microarray dataset 36 (unpaired Mann-Whitney U test, ****P < .0001) control group (NC, n = 10) ( Figure 3A,B) . Moreover, tissue analyses from mice killed 25 days post-injection revealed profound evidence of leukemia progression in mice injected with the SOCS5-depleted cells (SOCS5 KD1, n = 4; SOCS5 KD2, n = 4) compared to the control group (NC, n = 4). SOCS5 silencing significantly increased leukemia burden in bone marrow, brain, and liver of the tested mice ( Figure 3C ). PF382 cells did not infiltrate the spleen in all experimental groups, which is consistent with previously published data for PF382 cells. 41 These results show that SOCS5 downregulation promotes T-ALL cell proliferation in vivo, suggesting its suppressive role in leukemia engraftment and progression.
| SOCS5 expression is reduced in leukemic patients harboring KMT2A gene rearrangements
To determine SOCS5 expression in primary T-ALL, we assessed microarray data for 100 T-ALL samples obtained from children, adolescents, and young adults enrolled in COG AALL0434 (GSE70536), sought to determine whether SOCS5 mRNA levels were associated with recurrent chromosomal alterations found in T-ALL. We found that SOCS5 expression was downregulated in T-ALL patients harboring KMT2A gene rearrangements (KMT2A-R, P < .005; Figure 4C ). The results were consistent with our microarray dataset of 100 T-ALLs, in which KMT2A-R samples (n = 12) had lower levels of SOCS5 mRNA compared to the remaining samples ( Figure 4D ). To further validate our findings, we tested a limited number of primary T-ALL samples (n = 25; Table S4 ) and confirmed that both SOCS5 mRNA and protein are differentially expressed in T-ALL, and that samples harboring Table   S5 ). Figure 5C ). Together, these results indicate that SOCS5 downregulation is associated with KMT2A gene rearrangements and its lower levels enhance JAK-STAT and IL-7R signaling in T-ALL.
| SOCS5 downregulation potentiates IL-7-induced STAT5 activation
To determine whether SOCS5 inactivation reinforces the JAK-STAT signaling in response to IL-7 stimulation, we utilized primary T-ALL cells (ALL-214 and ALL-215) and cell lines (PF382 and ALL-SIL), which were stimulated with IL-7 (25 ng/mL; Figure 6 ). Under basal conditions, SOCS5-expressing PF382 cells showed the increase in 
| SOCS5 gene is differentially methylated in T-ALL
Because we did not identify any mutations in the SOCS5 gene in primary T-ALL samples ( Figure 4E ; not shown), we hypothesized that SOCS5 expression is regulated by DNA methylation in T-ALL. We analyzed the genomic sequence of SOCS5 ( Figure 7A ) spanning from −60 179 to −59 344 bps and identified densely clustered CpG islands around the promoter and the 1st exon. We performed a methylation-specific PCR using unmethylated or methylated DNA specific primers (Table S1 , Figure S4 ) to investigate the methylation of the 
| Histone deacetylation regulates SOCS5 expression
Methylated DNA can be bound by MBDs, which recruit multiprotein co-repressor complexes carrying HDACs to facilitate transcriptional repression. [45] [46] [47] We first tested whether histone deacetylation contributes to SOCS5 silencing by treating T-ALL cell lines with TSA, a potent inhibitor of class I and II HDACs, and found that TSA F I G U R E 7 DNA methylation regulates suppressor of cytokine signaling 5 (SOCS5) expression. A, Schematic diagram of the SOCS5 gene. Gray boxes represent exons; the translation start site is at +1, and the arrows indicate direction of translation. The bottom arrows indicate primers used for methylation specific PCR (MS-PCR). DNA methylation of SOCS5 promoter/1st exon in (B) T-cell lineage acute lymphoblastic leukemia (T-ALL) cell lines (n = 4) and (C) primary T-ALL samples (n = 12) and normal thymocytes (n = 3) were tested by methylation specific (MS)-PCR. M, methylated; U, unmethylated. D,E, Bisulfite sequencing of SOCS5 promoter/1st exon region in (D) T-ALL cell lines (n = 4) and (E) primary T-ALL samples (n = 6) for which sufficient DNA was available. Unmethylated CpG site in the amplified region is shown as an open, white circle and methylated CpG as a closed, black circle. F,G, DNA methylation (F) and bisulfite sequencing (G) of SOCS5 promoter/1st exon in ALL-SIL cells treated with demethylating agent 5-azacitidine (Aza) (24 h, 10 μmol/L) or vehicle control (Veh). H, Expression correlation between SOCS5 and DNA methyltransferase-3A (DNMT3A) in a previously published RNASeq dataset for 264 T-ALL patients from the COG study (NCT00408005) 1 (r, Pearson correlation; P < .0001). I, ALL-SIL cells were infected with scrambled control (NC) or lentivirus expressing shRNA targeting DNMT3A (DNMT3A KD1 and DNMT3A KD2). Knockdown of DNMT3A and SOCS5 gene expression was examined by quantitative real-time PCR and immunoblotting. SOCS5 in negative control cells (NC) was normalized to 1. Data are means ± SD for 3 independent experiments (****P < .0001; two-tailed Student's test). J,K, DNA methylation and bisulfite sequencing analyses of the SOCS5 promoter/1st exon in DNMT3A-depleted ALL-SIL cells compared to NC treatment induced SOCS5 mRNA and protein expression ( Figure   S6 ). To identify specific HDACs involved in the epigenetic regulation of SOCS5 expression, we carried out ChIP using Abs directed against HDAC1, HDAC2, and HDAC3 followed by qRT-PCR analyses. HDAC1 and HDAC2, but not HDAC3, occupied CpG islands at promoter/1st exon regions of the SOCS5 gene in ALL-SIL cells and primary T-ALL samples (n = 2; ALL-215 and ALL-216) ( Figure 8A ).
Because HDACs lack DNA binding domains, specific MBDs are required to mediate deacetylation of histone tails. To confirm whether HDAC1 and HDAC2 are recruited to the SOCS5 locus, we carried out ChIP against MeCP2, which is known to recruit SIN3 complex, 47, 48 and against MBD3, which is a core subunit of the NuRD complex. 46 The SIN3 and NuRD co-repressor complexes are commonly associated with HDAC1 and HDAC2. Our analyses show that SOCS5 is differentially expressed in primary T-ALL samples; however, we and others 1 did not identify mutations in the SOCS5 gene that might explain its expression profiles. Although mutations in the SOCS family genes are very rare, aberrant SOCS signaling has been linked to the epigenetic deregulation of their expression. 22, 23 For instance, reduced levels of SOCS5 mRNA and its promoter hypermethylation were reported in hepatocellular carcinoma, cervical cancer, and thyroid tumors. 21, 24 In this study, we dissected the mechanism of epigenetic deregulation of SOCS5 expression in T-ALL through aberrant DNA methylation. We showed that SOCS5 mRNA levels were closely associated with its promoter methylation. DNMT3A was identified to negatively regulate the SOCS5 expression levels in T-ALL cells. Histone acetylation has also been implicated in the epigenetic regulation of the SOCS family genes in solid tumors. 21 In addition, early studies identified the CpG binding protein, MeCP2 as a transcriptional silencer. 49, 50 Our ChIP analyses provide evidence that MeCP2 binds to the CpG islands of the SOCS5 promoter/1st exon and that MeCP2 regulation of SOCS5 expression is methylation-dependent. Furthermore, we identified the presence of HDAC1 and HDAC2 at the SOCS5 pro- Immunoprecipitates (Ac-H3) were subjected to qRT-PCR with primer pairs specific for SOCS5 promoter/1st exon region and for GAPDH, as a positive control that SOCS5 was downregulated in KMT2A-R T-ALL. In our study patients, ALL-144, ALL-138, and ALL-215 had KMT2A-R and almost undetectable SOCS5 protein levels ( Figure 4E ). We found that forced KMT2A-R expression lowered SOCS5 protein levels and led to increased activation of JAK-STAT signaling ( Figure 5A ). Our previous analyses on deregulated gene expression profiles in KMT2A-R T-ALL identified SOCS5 within the most downregulated genes. 53 Whether SOCS5 silencing is linked to KMT2A-R-driven oncogenesis in T-ALL and other acute leukemias remains unknown.
| D ISCUSS I ON
In line with previous studies, in which SOCS5 was proposed as a putative tumor suppressor, our results show that forced SOCS5 expression inhibited leukemic cell proliferation and cell cycle progression. Interestingly, apoptosis was not affected, suggesting that SOCS5 specifically regulates proliferation but not cell death in T-ALL. The results were consistent with our knockdown studies, in which SOCS5 inactivation accelerated cell growth and cell cycle progression in T-ALL cells. SOCS5 downregulation and its tumor suppressive role were reported in cervical and thyroid cancers. 21, 30, 31 However, in chronic lymphocytic leukemia patients, increased SOCS5 expression governed the defective function of dendritic cells. 54 Moreover, elevated SOCS5 protein levels were associated with unfavorable prognosis in liver and ovarian cancer (www.prote inatl as.org), strongly suggesting that the roles exerted by SOCS5 are 
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